Begoña Navarro-Almenzar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Begoña Navarro-Almenzar has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Faustino García-Candel
Haematology Service. Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain
2 shared publicationsJuan José Cerezo-Manchado
Haematology Service. Santa Lucía University General Hospital, Murcia, Spain
2 shared publicationsAlejandro Lova Navarro
Servicio de Cardiología. Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Universidad de Murcia, El Palmar, Spain
1 shared publicationAlmudena Cascales
Servicio de Hematología. Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB), Universidad de Murcia, El Palmar, Spain
1 shared publication- Arcadi García-Alberola
Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, 30120 Murcia, Spain
1 shared publication Beatriz Hurtado Oliver
Unidad de Cuidados Intensivos, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, España
1 shared publication
Latest Publications
- Open Access
- 11 November 2021
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 37, 100913
Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity
- 11 November 2021
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 37, 100913
Open AccessReal life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity
- Open Access
- 21 May 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (11) , 5451
Hereditary Hyperferritinemia Cataract Syndrome: Ferritin L Gene and Physiopathology behind the Disease—Report of New Cases
Hereditary hyperferritinemia-cataract syndrome (HHCS) is a rare disease characterized by high serum ferritin levels, congenital bilateral cataracts, and the absence of tissue iron overload. This disorder is produced by mutations in the iron responsive element (IRE) located in the 5′ untranslated regions (UTR) of the light ferritin (FTL) gene. A canonical IRE is a mRNA structure that interacts with the iron regulatory proteins (IRP1 and IRP2) to post-transcriptionally regulate the expression of proteins related to iron metabolism. Ferritin L and H are the proteins responsible for iron storage and intracellular distribution. Mutations in the FTL IRE abrogate the interaction of FTL mRNA with the IRPs, and de-repress the expression of FTL protein. Subsequently, there is an overproduction of ferritin that accumulates in serum (hyperferritinemia) and excess ferritin precipitates in the lens, producing cataracts. To illustrate this disease, we report two new families affected with hereditary hyperferritinemia-cataract syndrome with previous known mutations. In the diagnosis of congenital bilateral cataracts, HHCS should be taken into consideration and, therefore, it is important to test serum ferritin levels in patients with cataracts.
- 21 May 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (11) , 5451
Open AccessHereditary Hyperferritinemia Cataract Syndrome: Ferritin L Gene and Physiopathology behind the Disease—Report of New Cases
Hereditary hyperferritinemia-cataract syndrome (HHCS) is a rare disease characterized by high serum ferritin levels, congenital bilateral cataracts, and the absence of tissue iron overload. This disorder is produced by mutations in the iron responsive element (IRE) located in the 5′ untranslated regions (UTR) of the light ferritin (FTL) gene. A canonical IRE is a mRNA structure that interacts with the iron regulatory proteins (IRP1 and IRP2) to post-transcriptionally regulate the expression of proteins related to iron metabolism. Ferritin L and H are the proteins responsible for iron storage and intracellular distribution. Mutations in the FTL IRE abrogate the interaction of FTL mRNA with the IRPs, and de-repress the expression of FTL protein. Subsequently, there is an overproduction of ferritin that accumulates in serum (hyperferritinemia) and excess ferritin precipitates in the lens, producing cataracts. To illustrate this disease, we report two new families affected with hereditary hyperferritinemia-cataract syndrome with previous known mutations. In the diagnosis of congenital bilateral cataracts, HHCS should be taken into consideration and, therefore, it is important to test serum ferritin levels in patients with cataracts.
- 1 August 2020
- Published by Elsevier in Enfermedades Infecciosas y Microbiología Clínica
- Vol. 38 (7) , 341-342
Paciente de Guinea con shock séptico fulminante
- 1 August 2020
- Published by Elsevier in Enfermedades Infecciosas y Microbiología Clínica
- Vol. 38 (7) , 341-342
Paciente de Guinea con shock séptico fulminante
- 1 June 2020
- Published by Elsevier in Medicina Clinica
- Vol. 154 (11) , 473
Síndrome de secreción inadecuada de hormona antidiurética en paciente con linfoma difuso de células grandes B
- 1 June 2020
- Published by Elsevier in Medicina Clinica
- Vol. 154 (11) , 473
Síndrome de secreción inadecuada de hormona antidiurética en paciente con linfoma difuso de células grandes B
- 11 September 2019
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (12) , 2035-2041
Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry
Aim: To analyse the effectiveness and safety of DOAC (direct oral anticoagulants) in nonvalvular atrial fibrillation (NVAF) patients attending clinical practice. Methods: Retrospective study of AF patients who started treatment with DOAC from January 1, 2013 to December 31, 2016 in three Spanish hospitals. Mean follow up was 1.6 years. The primary outcomes were rates of all-cause death, ischemic stroke and bleeding. We also studied these outcomes depending on correct dosage adjustment and standard/adjusted dose. Results: The study included 2494 patients (age 76.0 ± 9.5 years, CHA2DS2-VASc =4.0 ± 1.6). The most prescribed DOAC was rivaroxaban (41.1%). Patients taking dabigatran were the youngest (mean age 73.1 ± 10.3 years), with better kidney function (mean CrCl 80.6 ± 35.8 ml/min) and lower CHA2DS2-VASc (3.7 ± 1.4) and HAS-BLED (2.1 ± 0.9) scores. Patients taking apixaban were the oldest, and had the highest CHA2DS2-VASc and HAS-BLED scores (4.3 ± 1.6 and 2.6 ± 0.9 respectively). Rates of stroke/major bleeding/intracranial bleeding were 1.8/3.0/0.3 events per 100 patient-years, respectively, with no differences among DOAC. Based on dose adjustment according to technical data, we observed that 517 patients (23.5%) received DOAC doses inconsistent with labelling (p < 0.001) and, within this group, underdosed patients had a higher death rate although it did not reach a significant result after multivariate adjustment. Conclusion: Our results of safety and efficacy are very similar to those of other previously published national registries. There were no differences among the different types of DOAC regarding outcomes. However, it was found that people taking the adjusted dose of the drug seemed to have a higher risk of death. A non-negligible proportion of patients received DOAC doses inconsistent with labelling (mostly underdose).
- 11 September 2019
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (12) , 2035-2041
Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry
Aim: To analyse the effectiveness and safety of DOAC (direct oral anticoagulants) in nonvalvular atrial fibrillation (NVAF) patients attending clinical practice. Methods: Retrospective study of AF patients who started treatment with DOAC from January 1, 2013 to December 31, 2016 in three Spanish hospitals. Mean follow up was 1.6 years. The primary outcomes were rates of all-cause death, ischemic stroke and bleeding. We also studied these outcomes depending on correct dosage adjustment and standard/adjusted dose. Results: The study included 2494 patients (age 76.0 ± 9.5 years, CHA2DS2-VASc =4.0 ± 1.6). The most prescribed DOAC was rivaroxaban (41.1%). Patients taking dabigatran were the youngest (mean age 73.1 ± 10.3 years), with better kidney function (mean CrCl 80.6 ± 35.8 ml/min) and lower CHA2DS2-VASc (3.7 ± 1.4) and HAS-BLED (2.1 ± 0.9) scores. Patients taking apixaban were the oldest, and had the highest CHA2DS2-VASc and HAS-BLED scores (4.3 ± 1.6 and 2.6 ± 0.9 respectively). Rates of stroke/major bleeding/intracranial bleeding were 1.8/3.0/0.3 events per 100 patient-years, respectively, with no differences among DOAC. Based on dose adjustment according to technical data, we observed that 517 patients (23.5%) received DOAC doses inconsistent with labelling (p < 0.001) and, within this group, underdosed patients had a higher death rate although it did not reach a significant result after multivariate adjustment. Conclusion: Our results of safety and efficacy are very similar to those of other previously published national registries. There were no differences among the different types of DOAC regarding outcomes. However, it was found that people taking the adjusted dose of the drug seemed to have a higher risk of death. A non-negligible proportion of patients received DOAC doses inconsistent with labelling (mostly underdose).